Introduction Outcome of liver disease in children is mainly determined by severity and progression of liver fibrosis. Liver biopsy is the accepted standard for evaluating fibrosis but is limited by the need for sedation in children, sampling error and risks including bleeding. Aim The aim of this study was to compare tools for non-invasive assessment of liver fibrosis in a paediatric cohort. Method Children were recruited at the time of liver biopsy and underwent transient elastography (TE) and blood collection. Liver biopsies were scored by a hepato-histopathologist from F0 (no fibrosis) to F4 (cirrhosis). Serum samples underwent analysis for the Enhanced Liver Fibrosis (ELF) test; comprising hyaluronic acid, P3NP and TIMP1 (iQur, UK). CK18-M30 levels (caspase cleavage fragments) were measured using ELISA. Biomarkers were compared to biopsy score. Results During the study period 101 children (62 boys) were enrolled. Median age: 13.6 (range 6e18) years. Diagnosis was autoimmune liver disease (AILD) in 27; non-alcoholic fatty liver disease (NAFLD) in 37; 13 children were post-transplant; 8 children had Hepatitis B/C; 5 had Wilson disease and the remainder miscellanous. TE was a good discriminator of fibrosis $ F2 (p<0.001), $ F3 (p<0.001) and F4 (p¼0.003) with areas under the ROC curve of 0.78, 0.8 and 0.96 respectively. Data derived cut-offs for $ F1 were 6.1 kPa, $ F2; 6.8 kPa, $ F3; 8.3 kPa and F4; 14.1 kPa.
Blood biomarkers were not as accurate in distinguishing severity of disease. ELF performed better with increasing stages of fibrosis. Area under the curve for cirrhosis was 0.77. CK18-M30 levels could distinguish significant fibrosis ($ F2) (p¼0.009) with an area under the ROC curve of 0.77, severe fibrosis ($ F3) with an AUROC of 0.69 and cirrhosis (F4) with an AUROC of 0.69. Within the different diagnostic groups, again TE performed better than serum biomarkers with AUROC of 0.75 for $ F2 and 0.81 for $ F3 in NAFLD; 0.85 for $ F2, 0.94 for $ F3 and 1.0 for F4 in AILD; and in children post-transplant; 0.9 for $ F2 and 0.83 for $ F3. Conclusion To our knowledge, this is the largest paediatric study reported to date comparing TE and serum biomarkers for the non-invasive evaluation of fibrosis. TEwas a reliable tool in distinguishing different stages of liver fibrosis in paediatric patients. Blood biomarkers may be of use in combination with TE especially in the stratification of more severe disease. Routine use of these techniques may serve as a useful adjunct to liver biopsy for diagnostic purposes and provide a reliable method of non-invasively monitoring liver disease progression in children.
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TIPS OUTCOMES FOR BUDDeCHIARI: A SINGLE TERTIARY CENTRE EXPERIENCE doi:10.1136/gutjnl-2011-300857a.17 Introduction TIPS insertion is an important intervention in the management of BuddeChiari syndrome. We describe the experience of a single tertiary referral centre. Aim The aims of this study were to describe the series of patients undergoing TIPS insertion for BuddeChiari syndrome at the Royal Free Hospital, survival post-TIPS insertion and re-intervention rates. Method A retrospective analysis of the Royal Free Hospital radiology database was conducted to identify all patients who underwent all TIPS procedures between January 1991 and January 2011. Patient records were used to subsequently identify those patients in whom BuddeChiari was the principal indication for TIPS insertion and to characterise this patient cohort. Results 1073 TIPS-related procedures were conducted at the Royal Free Hospital between January 1991 and January 2011. Of these, 51 patients underwent TIPS insertion for BuddeChiari syndrome between January 1991 and January 2011 of which 61% (31/51) were female and 39% (20/51) were male. The mean age at the time of TIPS insertion was 40 years (61.96). All patients were anticoagulated post procedure. 1-year transplant-free survival post-TIPS insertion was 93%. TIPS insertion could not be achieved in three patients. TIPS stenosis/occlusion was more common than in other TIPS indications. The mean number of TIPS-related interventions was 2.5 (1e10). Local thrombolysis with tissue plasminogen activator was required in three cases and patency/intervention rates were significantly improved with the addition of asprin to standard warfarin anticoagulation. No patients proceeded to liver transplantation. Regenerative nodules post TIPS were common on surveillance cross sectional imaging. Conclusion Excellent 1-year transplant-free survival can be obtained in BuddeChiari syndrome with TIPS placement. Patients are complex and may require multiple interventions and therefore probably best managed in experienced centres. Aim To assess baseline liver stiffness measurement (LSM) assessed by TE as a predictor of SVR in HCV-infected subjects treated with PEG-IFN+RBV. Method Retrospective review of outcomes of treatment in naïve patients treated with PEG-IFN+RBV for HCV between 7 January and 9 June. Post-transplant and co-infected patients were excluded. Patients who had valid LSM within 6 months of treatment were included in the TE analysis. Results 168 patients (mean age 39610, 70% male, 14% cirrhotic, 53% high viral load) received PEG-IFN+RBV for HCV in the study period. The overall SVR rate was 59% (50% for genotype [G] 1/4 and 70% for G2/3, p<0.001). The SVR rate was only 28% in cirrhotics (10% for G1/4 and 43% for G2/3). 87 patients had a pre-treatment TE (median LSM 6.6 KPa [3.3e73]).
P18 LIVER FIBROSIS ASSESSED BY TRANSIENT ELASTOGRAPHY PREDICTS RESPONSE IN CHRONIC HEPATITIS C INFECTED PATIENTS TREATED WITH PEG-INTERFERON AND RIBAVIRIN
LSM was significantly associated with treatment response to PEG-IFN (p¼0.01), with the effect more pronounced in HCV G2/3 infection (p¼0.001). The optimum cut-off to predict non-response to treatment was 11 KPa. 30 patients (16%) stopped treatment due to side-effects or non-compliance, including 1 death from pneumonitis. Conclusion (1) LSM determined by transient elastography may be used as a non-invasive tool to predict treatment response in subjects infected with HCV.
